← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics
fostamatinib
B02BX09
Forms & Strengths
- Oral tablets: 100 mg
- Oral tablets: 150 mg
Adult Dosing
- Initial dose: 100 mg orally twice daily
- Titration: Increase to 150 mg orally twice daily after 4 weeks if platelet count does not increase to at least 50 x 10^3/mcL
- Maximum dose: 150 mg twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment
Mechanism of Action
- Inhibits spleen tyrosine kinase (SYK)
- Interrupts Fc receptor signaling pathways and antibody-mediated destruction of platelets
Contraindications
- None significant identified in standard labeling
Adverse Reactions
- Diarrhea
- Hypertension
- Nausea
- Dizziness
- Elevated hepatic transaminases
- Respiratory tract infection
- Rash
- Fatigue
- Abdominal pain
- Neutropenia
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase fostamatinib metabolite R406 exposure; monitor for toxicity
- Strong CYP3A4 inducers (e.g., rifampin): May decrease R406 exposure and efficacy; avoid coadministration
- CYP3A4 substrates (e.g., simvastatin): May increase exposure of coadministered substrates
- BCRP substrates (e.g., rosuvastatin): May increase plasma concentrations and toxicity of BCRP substrates
Curated Content: Needs Vetting Before Put to Clinical Use